Covid-19 Impact on Metabolic Syndrome Market, Global Research Reports 2020-2021
This report covers market size and forecasts of Metabolic Syndrome, including the following market information:
Major competitors identified in this market include Novo Nordisk, Sanofi, Merck, AstraZeneca, Eli Lily, AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, etc.
Based on the Region:
- Global Metabolic Syndrome Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Metabolic Syndrome Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Metabolic Syndrome Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Metabolic Syndrome Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Major competitors identified in this market include Novo Nordisk, Sanofi, Merck, AstraZeneca, Eli Lily, AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, etc.
Based on the Region:
- Asia-Pacific (China, Japan, South Korea, India and ASEAN)
- North America (US and Canada)
- Europe (Germany, France, UK and Italy)
- Rest of World (Latin America, Middle East & Africa)
- Diabetes
- Obesity
- Hypercholesterolemia
- Lysosomal storage diseases
- Hospital
- Clinic
- Others
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Metabolic Syndrome Industry
1.7 COVID-19 Impact: Metabolic Syndrome Market Trends
2 GLOBAL METABOLIC SYNDROME QUARTERLY MARKET SIZE ANALYSIS
2.1 Metabolic Syndrome Business Impact Assessment - COVID-19
2.1.1 Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Metabolic Syndrome Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Metabolic Syndrome Quarterly Market Size, 2019 VS 2020
3.2 By Players, Metabolic Syndrome Headquarters and Area Served
3.3 Date of Key Players Enter into Metabolic Syndrome Market
3.4 Key Players Metabolic Syndrome Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON METABOLIC SYNDROME SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Diabetes
1.4.2 Obesity
1.4.3 Hypercholesterolemia
1.4.4 Lysosomal storage diseases
4.2 By Type, Global Metabolic Syndrome Market Size, 2019-2021
5 IMPACT OF COVID-19 ON METABOLIC SYNDROME SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Hospital
5.5.2 Clinic
5.5.3 Others
5.2 By Application, Global Metabolic Syndrome Market Size, 2019-2021
5.2.1 By Application, Global Metabolic Syndrome Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Novo Nordisk
7.1.1 Novo Nordisk Business Overview
7.1.2 Novo Nordisk Metabolic Syndrome Quarterly Revenue, 2020
7.1.3 Novo Nordisk Metabolic Syndrome Product Introduction
7.1.4 Novo Nordisk Response to COVID-19 and Related Developments
7.2 Sanofi
7.2.1 Sanofi Business Overview
7.2.2 Sanofi Metabolic Syndrome Quarterly Revenue, 2020
7.2.3 Sanofi Metabolic Syndrome Product Introduction
7.2.4 Sanofi Response to COVID-19 and Related Developments
7.3 Merck
7.3.1 Merck Business Overview
7.3.2 Merck Metabolic Syndrome Quarterly Revenue, 2020
7.3.3 Merck Metabolic Syndrome Product Introduction
7.3.4 Merck Response to COVID-19 and Related Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Business Overview
7.4.2 AstraZeneca Metabolic Syndrome Quarterly Revenue, 2020
7.4.3 AstraZeneca Metabolic Syndrome Product Introduction
7.4.4 AstraZeneca Response to COVID-19 and Related Developments
7.5 Eli Lily
7.5.1 Eli Lily Business Overview
7.5.2 Eli Lily Metabolic Syndrome Quarterly Revenue, 2020
7.5.3 Eli Lily Metabolic Syndrome Product Introduction
7.5.4 Eli Lily Response to COVID-19 and Related Developments
7.6 AbbVie
7.6.1 AbbVie Business Overview
7.6.2 AbbVie Metabolic Syndrome Quarterly Revenue, 2020
7.6.3 AbbVie Metabolic Syndrome Product Introduction
7.6.4 AbbVie Response to COVID-19 and Related Developments
7.7 Actelion Pharmaceuticals
7.7.1 Actelion Pharmaceuticals Business Overview
7.7.2 Actelion Pharmaceuticals Metabolic Syndrome Quarterly Revenue, 2020
7.7.3 Actelion Pharmaceuticals Metabolic Syndrome Product Introduction
7.7.4 Actelion Pharmaceuticals Response to COVID-19 and Related Developments
7.8 Adocia
7.8.1 Adocia Business Overview
7.8.2 Adocia Metabolic Syndrome Quarterly Revenue, 2020
7.8.3 Adocia Metabolic Syndrome Product Introduction
7.8.4 Adocia Response to COVID-19 and Related Developments
7.9 Aegerion Pharmaceuticals
7.9.1 Aegerion Pharmaceuticals Business Overview
7.9.2 Aegerion Pharmaceuticals Metabolic Syndrome Quarterly Revenue, 2020
7.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Product Introduction
7.9.4 Aegerion Pharmaceuticals Response to COVID-19 and Related Developments
7.10 Akros Pharma
7.10.1 Akros Pharma Business Overview
7.10.2 Akros Pharma Metabolic Syndrome Quarterly Revenue, 2020
7.10.3 Akros Pharma Metabolic Syndrome Product Introduction
7.10.4 Akros Pharma Response to COVID-19 and Related Developments
7.11 Alnylam Pharmaceuticals
7.11.1 Alnylam Pharmaceuticals Business Overview
7.11.2 Alnylam Pharmaceuticals Metabolic Syndrome Quarterly Revenue, 2020
7.11.3 Alnylam Pharmaceuticals Metabolic Syndrome Product Introduction
7.11.4 Alnylam Pharmaceuticals Response to COVID-19 and Related Developments
7.12 Amarin
7.12.1 Amarin Business Overview
7.12.2 Amarin Metabolic Syndrome Quarterly Revenue, 2020
7.12.3 Amarin Metabolic Syndrome Product Introduction
7.12.4 Amarin Response to COVID-19 and Related Developments
7.13 nAmgen
7.13.1 nAmgen Business Overview
7.13.2 nAmgen Metabolic Syndrome Quarterly Revenue, 2020
7.13.3 nAmgen Metabolic Syndrome Product Introduction
7.13.4 nAmgen Response to COVID-19 and Related Developments
7.14 Amicus Therapeutics
7.14.1 Amicus Therapeutics Business Overview
7.14.2 Amicus Therapeutics Metabolic Syndrome Quarterly Revenue, 2020
7.14.3 Amicus Therapeutics Metabolic Syndrome Product Introduction
7.14.4 Amicus Therapeutics Response to COVID-19 and Related Developments
7.15 Arbutus Biopharma
7.15.1 Arbutus Biopharma Business Overview
7.15.2 Arbutus Biopharma Metabolic Syndrome Quarterly Revenue, 2020
7.15.3 Arbutus Biopharma Metabolic Syndrome Product Introduction
7.15.4 Arbutus Biopharma Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Metabolic Syndrome Industry
1.7 COVID-19 Impact: Metabolic Syndrome Market Trends
2 GLOBAL METABOLIC SYNDROME QUARTERLY MARKET SIZE ANALYSIS
2.1 Metabolic Syndrome Business Impact Assessment - COVID-19
2.1.1 Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Metabolic Syndrome Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Metabolic Syndrome Quarterly Market Size, 2019 VS 2020
3.2 By Players, Metabolic Syndrome Headquarters and Area Served
3.3 Date of Key Players Enter into Metabolic Syndrome Market
3.4 Key Players Metabolic Syndrome Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON METABOLIC SYNDROME SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Diabetes
1.4.2 Obesity
1.4.3 Hypercholesterolemia
1.4.4 Lysosomal storage diseases
4.2 By Type, Global Metabolic Syndrome Market Size, 2019-2021
5 IMPACT OF COVID-19 ON METABOLIC SYNDROME SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Hospital
5.5.2 Clinic
5.5.3 Others
5.2 By Application, Global Metabolic Syndrome Market Size, 2019-2021
5.2.1 By Application, Global Metabolic Syndrome Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Novo Nordisk
7.1.1 Novo Nordisk Business Overview
7.1.2 Novo Nordisk Metabolic Syndrome Quarterly Revenue, 2020
7.1.3 Novo Nordisk Metabolic Syndrome Product Introduction
7.1.4 Novo Nordisk Response to COVID-19 and Related Developments
7.2 Sanofi
7.2.1 Sanofi Business Overview
7.2.2 Sanofi Metabolic Syndrome Quarterly Revenue, 2020
7.2.3 Sanofi Metabolic Syndrome Product Introduction
7.2.4 Sanofi Response to COVID-19 and Related Developments
7.3 Merck
7.3.1 Merck Business Overview
7.3.2 Merck Metabolic Syndrome Quarterly Revenue, 2020
7.3.3 Merck Metabolic Syndrome Product Introduction
7.3.4 Merck Response to COVID-19 and Related Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Business Overview
7.4.2 AstraZeneca Metabolic Syndrome Quarterly Revenue, 2020
7.4.3 AstraZeneca Metabolic Syndrome Product Introduction
7.4.4 AstraZeneca Response to COVID-19 and Related Developments
7.5 Eli Lily
7.5.1 Eli Lily Business Overview
7.5.2 Eli Lily Metabolic Syndrome Quarterly Revenue, 2020
7.5.3 Eli Lily Metabolic Syndrome Product Introduction
7.5.4 Eli Lily Response to COVID-19 and Related Developments
7.6 AbbVie
7.6.1 AbbVie Business Overview
7.6.2 AbbVie Metabolic Syndrome Quarterly Revenue, 2020
7.6.3 AbbVie Metabolic Syndrome Product Introduction
7.6.4 AbbVie Response to COVID-19 and Related Developments
7.7 Actelion Pharmaceuticals
7.7.1 Actelion Pharmaceuticals Business Overview
7.7.2 Actelion Pharmaceuticals Metabolic Syndrome Quarterly Revenue, 2020
7.7.3 Actelion Pharmaceuticals Metabolic Syndrome Product Introduction
7.7.4 Actelion Pharmaceuticals Response to COVID-19 and Related Developments
7.8 Adocia
7.8.1 Adocia Business Overview
7.8.2 Adocia Metabolic Syndrome Quarterly Revenue, 2020
7.8.3 Adocia Metabolic Syndrome Product Introduction
7.8.4 Adocia Response to COVID-19 and Related Developments
7.9 Aegerion Pharmaceuticals
7.9.1 Aegerion Pharmaceuticals Business Overview
7.9.2 Aegerion Pharmaceuticals Metabolic Syndrome Quarterly Revenue, 2020
7.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Product Introduction
7.9.4 Aegerion Pharmaceuticals Response to COVID-19 and Related Developments
7.10 Akros Pharma
7.10.1 Akros Pharma Business Overview
7.10.2 Akros Pharma Metabolic Syndrome Quarterly Revenue, 2020
7.10.3 Akros Pharma Metabolic Syndrome Product Introduction
7.10.4 Akros Pharma Response to COVID-19 and Related Developments
7.11 Alnylam Pharmaceuticals
7.11.1 Alnylam Pharmaceuticals Business Overview
7.11.2 Alnylam Pharmaceuticals Metabolic Syndrome Quarterly Revenue, 2020
7.11.3 Alnylam Pharmaceuticals Metabolic Syndrome Product Introduction
7.11.4 Alnylam Pharmaceuticals Response to COVID-19 and Related Developments
7.12 Amarin
7.12.1 Amarin Business Overview
7.12.2 Amarin Metabolic Syndrome Quarterly Revenue, 2020
7.12.3 Amarin Metabolic Syndrome Product Introduction
7.12.4 Amarin Response to COVID-19 and Related Developments
7.13 nAmgen
7.13.1 nAmgen Business Overview
7.13.2 nAmgen Metabolic Syndrome Quarterly Revenue, 2020
7.13.3 nAmgen Metabolic Syndrome Product Introduction
7.13.4 nAmgen Response to COVID-19 and Related Developments
7.14 Amicus Therapeutics
7.14.1 Amicus Therapeutics Business Overview
7.14.2 Amicus Therapeutics Metabolic Syndrome Quarterly Revenue, 2020
7.14.3 Amicus Therapeutics Metabolic Syndrome Product Introduction
7.14.4 Amicus Therapeutics Response to COVID-19 and Related Developments
7.15 Arbutus Biopharma
7.15.1 Arbutus Biopharma Business Overview
7.15.2 Arbutus Biopharma Metabolic Syndrome Quarterly Revenue, 2020
7.15.3 Arbutus Biopharma Metabolic Syndrome Product Introduction
7.15.4 Arbutus Biopharma Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
LIST OF TABLES
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Metabolic Syndrome Assessment
Table 9. COVID-19 Impact: Metabolic Syndrome Market Trends
Table 10. COVID-19 Impact Global Metabolic Syndrome Market Size
Table 11. Global Metabolic Syndrome Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Metabolic Syndrome Market Growth Drivers
Table 14. Global Metabolic Syndrome Market Restraints
Table 15. Global Metabolic Syndrome Market Opportunities
Table 16. Global Metabolic Syndrome Market Challenges
Table 17. By Players, Metabolic Syndrome Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Metabolic Syndrome Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Metabolic Syndrome Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Metabolic Syndrome Market
Table 21. Key Players Metabolic Syndrome Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Metabolic Syndrome Market Size 2019-2021, (US$ Million)
Table 24. Global Metabolic Syndrome Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Metabolic Syndrome Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 57. Novo Nordisk Business Overview
Table 58. Novo Nordisk Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Novo Nordisk Metabolic Syndrome Product
Table 60. Novo Nordisk Response to COVID-19 and Related Developments
Table 61. Sanofi Business Overview
Table 62. Sanofi Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Sanofi Metabolic Syndrome Product
Table 64. Sanofi Response to COVID-19 and Related Developments
Table 65. Merck Business Overview
Table 66. Merck Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Merck Metabolic Syndrome Product
Table 68. Merck Response to COVID-19 and Related Developments
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. AstraZeneca Metabolic Syndrome Product
Table 72. AstraZeneca Response to COVID-19 and Related Developments
Table 73. Eli Lily Business Overview
Table 74. Eli Lily Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Eli Lily Metabolic Syndrome Product
Table 76. Eli Lily Response to COVID-19 and Related Developments
Table 77. AbbVie Business Overview
Table 78. AbbVie Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. AbbVie Metabolic Syndrome Product
Table 80. AbbVie Response to COVID-19 and Related Developments
Table 81. Actelion Pharmaceuticals Business Overview
Table 82. Actelion Pharmaceuticals Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Actelion Pharmaceuticals Metabolic Syndrome Product
Table 84. Actelion Pharmaceuticals Response to COVID-19 and Related Developments
Table 85. Adocia Business Overview
Table 86. Adocia Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Adocia Metabolic Syndrome Product
Table 88. Adocia Response to COVID-19 and Related Developments
Table 89. Aegerion Pharmaceuticals Business Overview
Table 90. Aegerion Pharmaceuticals Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Aegerion Pharmaceuticals Metabolic Syndrome Product
Table 92. Aegerion Pharmaceuticals Response to COVID-19 and Related Developments
Table 93. Akros Pharma Business Overview
Table 94. Akros Pharma Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Akros Pharma Metabolic Syndrome Product
Table 96. Akros Pharma Response to COVID-19 and Related Developments
Table 97. Alnylam Pharmaceuticals Business Overview
Table 98. Alnylam Pharmaceuticals Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Alnylam Pharmaceuticals Metabolic Syndrome Product
Table 100. Alnylam Pharmaceuticals Response to COVID-19 and Related Developments
Table 101. Amarin Business Overview
Table 102. Amarin Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 103. Amarin Metabolic Syndrome Product
Table 104. Amarin Response to COVID-19 and Related Developments
Table 105. nAmgen Business Overview
Table 106. nAmgen Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 107. nAmgen Metabolic Syndrome Product
Table 108. nAmgen Response to COVID-19 and Related Developments
Table 109. Amicus Therapeutics Business Overview
Table 110. Amicus Therapeutics Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 111. Amicus Therapeutics Metabolic Syndrome Product
Table 112. Amicus Therapeutics Response to COVID-19 and Related Developments
Table 113. Arbutus Biopharma Business Overview
Table 114. Arbutus Biopharma Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 115. Arbutus Biopharma Metabolic Syndrome Product
Table 116. Arbutus Biopharma Response to COVID-19 and Related Developments
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Metabolic Syndrome Assessment
Table 9. COVID-19 Impact: Metabolic Syndrome Market Trends
Table 10. COVID-19 Impact Global Metabolic Syndrome Market Size
Table 11. Global Metabolic Syndrome Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Metabolic Syndrome Market Growth Drivers
Table 14. Global Metabolic Syndrome Market Restraints
Table 15. Global Metabolic Syndrome Market Opportunities
Table 16. Global Metabolic Syndrome Market Challenges
Table 17. By Players, Metabolic Syndrome Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Metabolic Syndrome Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Metabolic Syndrome Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Metabolic Syndrome Market
Table 21. Key Players Metabolic Syndrome Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Metabolic Syndrome Market Size 2019-2021, (US$ Million)
Table 24. Global Metabolic Syndrome Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Metabolic Syndrome Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Metabolic Syndrome Market Size, 2019-2021 (US$ Million)
Table 57. Novo Nordisk Business Overview
Table 58. Novo Nordisk Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Novo Nordisk Metabolic Syndrome Product
Table 60. Novo Nordisk Response to COVID-19 and Related Developments
Table 61. Sanofi Business Overview
Table 62. Sanofi Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Sanofi Metabolic Syndrome Product
Table 64. Sanofi Response to COVID-19 and Related Developments
Table 65. Merck Business Overview
Table 66. Merck Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Merck Metabolic Syndrome Product
Table 68. Merck Response to COVID-19 and Related Developments
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. AstraZeneca Metabolic Syndrome Product
Table 72. AstraZeneca Response to COVID-19 and Related Developments
Table 73. Eli Lily Business Overview
Table 74. Eli Lily Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Eli Lily Metabolic Syndrome Product
Table 76. Eli Lily Response to COVID-19 and Related Developments
Table 77. AbbVie Business Overview
Table 78. AbbVie Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. AbbVie Metabolic Syndrome Product
Table 80. AbbVie Response to COVID-19 and Related Developments
Table 81. Actelion Pharmaceuticals Business Overview
Table 82. Actelion Pharmaceuticals Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Actelion Pharmaceuticals Metabolic Syndrome Product
Table 84. Actelion Pharmaceuticals Response to COVID-19 and Related Developments
Table 85. Adocia Business Overview
Table 86. Adocia Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Adocia Metabolic Syndrome Product
Table 88. Adocia Response to COVID-19 and Related Developments
Table 89. Aegerion Pharmaceuticals Business Overview
Table 90. Aegerion Pharmaceuticals Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Aegerion Pharmaceuticals Metabolic Syndrome Product
Table 92. Aegerion Pharmaceuticals Response to COVID-19 and Related Developments
Table 93. Akros Pharma Business Overview
Table 94. Akros Pharma Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Akros Pharma Metabolic Syndrome Product
Table 96. Akros Pharma Response to COVID-19 and Related Developments
Table 97. Alnylam Pharmaceuticals Business Overview
Table 98. Alnylam Pharmaceuticals Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Alnylam Pharmaceuticals Metabolic Syndrome Product
Table 100. Alnylam Pharmaceuticals Response to COVID-19 and Related Developments
Table 101. Amarin Business Overview
Table 102. Amarin Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 103. Amarin Metabolic Syndrome Product
Table 104. Amarin Response to COVID-19 and Related Developments
Table 105. nAmgen Business Overview
Table 106. nAmgen Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 107. nAmgen Metabolic Syndrome Product
Table 108. nAmgen Response to COVID-19 and Related Developments
Table 109. Amicus Therapeutics Business Overview
Table 110. Amicus Therapeutics Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 111. Amicus Therapeutics Metabolic Syndrome Product
Table 112. Amicus Therapeutics Response to COVID-19 and Related Developments
Table 113. Arbutus Biopharma Business Overview
Table 114. Arbutus Biopharma Metabolic Syndrome Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 115. Arbutus Biopharma Metabolic Syndrome Product
Table 116. Arbutus Biopharma Response to COVID-19 and Related Developments
LIST OF FIGURES
Figure 1. Metabolic Syndrome Product Picture
Figure 2. Metabolic Syndrome Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Metabolic Syndrome Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Metabolic Syndrome Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Metabolic Syndrome Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Metabolic Syndrome Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Metabolic Syndrome Market Size Market Share, 2019-2021
Figure 1. Metabolic Syndrome Product Picture
Figure 2. Metabolic Syndrome Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Metabolic Syndrome Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Metabolic Syndrome Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Metabolic Syndrome Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Metabolic Syndrome Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Metabolic Syndrome Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Metabolic Syndrome Market Size Market Share, 2019-2021
